Merck announces positive results from two phase III trials (ILLUMINATE SWITCH A and ILLUMINATE SWITCH B) evaluating investigational, once-daily oral fixed dose combination of doravirine/islatravir (DOR/ISL) for treatment of HIV

At 48 weeks, both trials met primary efficacy endpoint of proportion patients with HIV-1 RNA levels ≥50 copies/mL, demonstrating comparable antiviral efficacy between DOR/ISL & antiretroviral therapy (SWITCH A) and between DOR/ISL & bictegravir/emtricitabine/tenofovir (SWITCH B).

SPS commentary:

Detailed findings from these studies will be presented at a future scientific congress and will form the basis of global regulatory applications.

Doravirine is currently licensed for the treatment of adults with HIV in combination with other antiretrovirals, as a single agent (Pifeltro) and a component of a single-tablet regimen (with lamivudine and tenofovir disoproxil fumarate [Delstrigo]). Islatravir is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation for the treatment of HIV in combination with other antiretrovirals.

Biospace Inc.